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Atrial fibrillation (AF) and valvular heart disease (VHD) increase 
the risk of thrombus-related morbidity and cardioembolic stroke.[1] 
Stroke is one of the top four causes of death and adult disability in 
South Africa (SA).[2,3] Appropriately dosed anticoagulation therapy 
decreases morbidity and mortality due to cardioembolic stroke.[4-6]
Warfarin is the most widely used oral anticoagulant for primary 
and secondary stroke prevention[7] and is the only vitamin K 
antagonist (VKA) available in SA.[8] Alternative oral anticoagulants 
are not routinely available in public sector healthcare facilities owing 
to their high cost.[9] Aspirin is a poor alternative in patients with AF, 
as it is much less effective at preventing cardioembolic events.[7,10] 
Warfarin has unpredictable pharmacokinetics and dynamics, and 
requires individualised dosing to achieve optimal anticoagulation. 
Warfarin has a narrow therapeutic range, placing patients at risk 
of bleeding if the target is exceeded and at risk of thromboembolic 
complications if subtherapeutic.[5,10] Warfarin is a leading cause of 
adverse drug reaction (ADR)-related medical admissions in SA.[11]
Time in the therapeutic range (TTR) is a calculation that reflects 
the duration of time in which a patient’s international normalised 
ratio (INR) values were within the desired range and is used 
to evaluate the effectiveness of warfarin therapy. For effective 
anticoagulation, patients on warfarin should achieve an INR in 
the therapeutic range for ≥65% of the follow-up time.[10] Patients 
with TTR <65% have reduced warfarin efficacy.[10] Low TTR is also 
associated with an increased risk of both bleeding and thrombo-
embolic complications. [10] Two multinational multicentre clinical 
trials (ACTIVE W and RE-LY) that included patients from SA found 
poor INR control in SA patients receiving warfarin.[10,12]
Objectives
We quantified anticoagulation control over a 6-month period for 
patients on long-term warfarin managed at two dedicated INR 
clinics in Cape Town, SA. Specific objectives were to determine 
the proportion of patients achieving a TTR ≥65%, and to identify 
predictors of adequate control (TTR ≥65%).
Methods
We reviewed folders of patients attending the warfarin anticoagulation 
monitoring clinics at Mitchell’s Plain Community Health Centre 
(MPC) and Groote Schuur Hospital (GSH) in Cape Town. These 
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Background. Warfarin is the most commonly used anticoagulant for both primary and secondary prevention of thromboembolism. For 
anticoagulation efficacy, the international normalised ratio (INR) needs to be within the therapeutic range for at least 65% of time on warfarin.
Objectives. To describe INR control in patients on long-term warfarin and identified predictors of good INR control at two dedicated warfarin 
follow-up clinics in Cape Town, South Africa (SA).
Methods. We reviewed clinical records of patients in care at the INR clinics at Mitchell’s Plain Community Health Centre and Groote Schuur 
Hospital. We included patients who had been on warfarin therapy for at least 27 months and excluded patients with <6 months of INR 
monitoring data or a >70-day gap between INR tests in the calculation period, and if >25% of follow-up time was at an alternative site. The 
time in therapeutic range (TTR) over 180 days using the Rosendaal method was calculated, and we categorised INR control as good if the TTR 
was ≥65%. We constructed a multivariate logistic regression model to identify associations with good INR control.
Results. We included 363 patients, with a median age of 55 years (interquartile range (IQR) 44 - 64), of whom 65.6% were women. The most 
common indications for warfarin were valvular heart disease (45.7%) and atrial fibrillation (25.1%). The mean TTR was 47%, with only 91/363 
patients having good INR control. In a multivariate model adjusted for age, sex, clinic and target INR, patients aged ≥55 years were more likely 
to have good INR control than younger patients (adjusted odds ratio 1.69, 95% confidence interval 1.03 - 2.79). Poorly controlled patients had 
more frequent INR monitoring than those with good INR control, with a median of 8 INRs (IQR 6 - 10) v. 6 INRs (IQR 5 - 8) in the 180-day 
period (p<0.0001).
Conclusions. Only 25.1% of patients in our study achieved good INR control, despite regular INR monitoring. There is an urgent need to 
improve anticoagulation control of patients receiving warfarin in SA. Validated dosing algorithms are required, and access to lower warfarin 
dosage formulations may optimise individual dose titration. Advocacy for these formulations is advised.
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outpatient clinics assess the INR at patient 
visits and adjust the warfarin dose in 
response to the INR result. At GSH, INR 
results are available within hours and dose 
modification occurs immediately. At MPC, 
INR results are available the next day and 
dose adjustment instructions are given to 
patients telephonically. Both facilities use the 
same, unvalidated dosing algorithm to guide 
dose adjustments.
We identified patients who were on long-
term warfarin therapy, which we defined as 
at least 2 years on warfarin, after an initial 
3-month dose-stabilisation period to achieve 
the required INR. The INR monitoring 
results were reviewed, and we excluded 
patients with <6 months of consecutive 
INR data and those who visited both or 
other sites and had >25% of follow-up visits 
at an alternative site. We also excluded 
patients who had >70 days between INR 
quantification.[13] Patient follow-up at clinics 
occurs at least every 2 months (56 days) and 
we allowed for patients to be 14 days late for 
routine follow-up. We excluded patients with 
larger gaps between INRs as this may affect 
the accuracy of TTR quantification and 
under- or overestimate the TTR.[13]
We powered the study to detect a 15% 
difference in the mean TTR between the 
two sites (with α=0.05 and 80% power) and 
calculated that we would need 173 patients 
from each site for a total sample size of 346.
We calculated the TTR using the widely 
accepted Rosendaal method.[13] The calcu la-
tion assumes a linear relationship (increase 
or decrease) between consecutive INR 
values to determine the proportion of time 
within the therapeutic range.[13] We calcu-
lated TTR over 6 months (180 days) and 
excluded the first 90 days of regular INR 
monitoring data from the TTR calculation, 
to allow patients newly initiated on warfarin 
to achieve stability. TTR was therefore 
calculated starting from the first INR result 
after the 90-day window. The target INR 
range for patients taking warfarin for AF 
and most other indications is 2.0 - 3.0. The 
target INR range for VHD is 2.5 - 3.5.[14] The 
therapeutic range for the patient’s clinical 
condition was used as the target for that 
patient in the TTR calculation. In patients 
with an unknown indication for warfarin 
therapy, we assumed a target INR range of 
2.0 - 3.0. We defined poor control as TTR 
<65% over the 180-day period, and good 
control as TTR ≥65%.[10]
Statistical analysis
We summarised continuous variables as 
means (standard deviation (SD)) if normally 
distributed and as medians with interquartile 
ranges (IQRs) if abnormally distributed, 
and used the Wilcoxon rank-sum test for 
between-group comparisons of continuous 
variables. Univariate associations between 
categorical variables were explored using the 
χ2 test. We constructed a multivariate logistic 
regression model of associations with good 
anticoagulation (TTR ≥65%), and included 
age, sex, site and target INR in the model 
based on an a priori decision. Age was split 
into two groups at the median and included 
in the model as a binary variable. A p-value 
<0.05 was considered statistically significant. 
Stata SE 13.1 (StataCorp, USA) was used for 
the analyses.
Ethical considerations
The study was approved by the Human 
Research Ethics Committee at the University 
of Cape Town (ref. no. 658/2014) and the 
Western Cape Health Research Committee 
(ref. no. WC_2015RP8_111). Permission to 
conduct the research was given by hospital 
management of MPC and GSH. The study was 
conducted in accordance with the Declara-
tion of Helsinki (last updated 2013)[15] and the 
Guideline for Good Clinical Practice.[16]
Results
We screened the clinical records of 949 
patients, of whom 586 were excluded and 
363 were included in the analysis (Fig. 1). 
Screening took place in September 2014. 
INR data were reviewed between 2009 and 
2014, and all participants with more than 
27 months of INR data were included in 
the study.
Patient characteristics are set out in Table 1. 
The most common indications for warfarin 
therapy were AF (25.1%) and VHD (45.7%). 
Other indications were pulmonary embolus, 
venous thromboembolism, systemic lupus 
erythematosus, hypercoagulable states and 
atrial flutter. An indication was not docu-
mented in 10.5% of patients.
The mean (SD) TTR was 47.0% (24.0%) 
and did not differ significantly between sites 
(Fig. 2). In 272/363 patients (74.9%) the 
TTR was <65%. Poorly controlled patients 
had more frequent INR monitoring than 
those with good control, with a median 
of 8 readings (IQR 6 - 10) and 6 readings 
(IQR 5.0 - 8.0) over the 6-month period, 
respectively (rank-sum p<0.0001). Patients 
aged <55 years had a mean TTR of 43% 
(95% confidence interval (CI) 40 - 47) 
compared with a mean of 50% for those aged 
≥55  years (95% CI 46 - 53) (p=0.0105). In 
the multivariate analysis, age ≥55 years was 
associated with better INR control (Table 2).
Discussion
The majority of patients in our study had 
poor INR control – only 25.1% had a TTR 
≥65%. Older age was associated with better 
control, but even in patients aged ≥55 
years, only 30.6% achieved a TTR of ≥65% 
(Table  2). This is a concerning finding. 
Despite regular follow-up, most patients 
did not achieve adequate INR control for 
efficacy and are at risk of warfarin adverse 
effects.
Even under clinical trial conditions, 
anticoagulation control of South Afri-
cans taking warfarin was poor. SA partici-
Patient records screened
N=949
INR monitoring results reviewed
n=466 patients
Patients included in the analysis
n=363 (MPC n=151, GSH n=212)
Patients excluded, n=483
• <27 months on warfarin
Patients excluded, n=103
• <6 months INR monitoring, n=60
• >70 days between consecutive INRs, n=23
• >25% of follow-up time at alternative clinic, n=20
Fig. 1. Selection of patients included in the analysis. (INR = international normalised ratio; MPC = 
Mitchell’s Plain Community Health Centre; GSH = Groote Schuur Hospital.)
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pants with AF randomised to warfarin in the international 
multicentre ACTIVE-W trial (dual antiplatelet therapy v. warfarin 
anticoagulation) had a mean TTR of 46%.[10] In the RELY trial 
(randomised evaluation of long-term anticoagulation therapy), 
which randomised participants with AF to dabigatran or warfarin, 
the mean TTR of SA participants was 58%.[12]
In keeping with our findings, in an earlier study[17] only 50% of 
patients in Cape Town receiving warfarin for rheumatic heart disease 
had good anticoagulation control as measured by TTR calculated 
by the Rosendaal method, but only three INR readings were used in 
this study. A cross-sectional study at Victoria Hospital in Cape Town 
found that only 49% of patients had a therapeutic INR.[18] There are 
few African studies outside SA. In an Ethiopian cross-sectional study, 
only 30.3% of patients had a therapeutic INR.[19] These cross-sectional 
studies are limited in their design by the fact that they only provide 
a snapshot of INR control at a single time point. The association 
between older age and improved control that we observed is in 
keeping with findings from other studies.[18,20] The Victoria Hospital 
study in Cape Town found that patients aged ≥60 years were more 
likely than younger patients to have a therapeutic INR. A Swedish 
study also found a correlation between improved TTR and older age.
[18,20] We found no association between INR control and sex, similar to 
the study at Victoria Hospital.[18] INR control did not differ between 
the two clinics in our study.
Patients with poor anticoagulation control (TTR <65%) had more 
frequent INR monitoring than those with good control, but despite 
regular monitoring to guide dose adjustments, INR control was poor 
in these patients. This may reflect flaws in the unvalidated algorithm 
used to guide warfarin dose adjustment at our study sites.
Poor INR control may result in serious clinical consequences. A 
recent SA survey found that warfarin was the fourth most commonly 
implicated drug in ADR-related admissions and the most commonly 
implicated drug in preventable ADR-related admissions.[11] A median 
Table 1. Characteristics of included patients (N=363)
MPC GSH
Patients, n (%) 151 (41.3) 212 (58.4)
Female sex 100 (66.2) 138 (65.1)
Age (years), median (IQR) 57 (48 - 66) 53 (41 - 62)
Target INR range, n (%)
2.0 - 3.0* 121 (80.1) 76 (35.9)
2.5 - 3.5† 30 (19.9) 136 (64.2)
MPC = Mitchell’s Plain Community Health Centre; GSH = Groote Schuur Hospital; IQR = interquartile range; INR = international normalised ratio.
*Target INR range of 2.0 - 3.0 for patients anticoagulated with warfarin because of atrial fibrillation, pulmonary embolus, venous thromboembolism, systemic lupus erythematosus, 
hypercoagulable states, atrial flutter or undocumented indication.
†Target INR range of 2.5 - 3.5 for patients anticoagulated with warfarin because they had valvular heart disease.Figure 2. Scatter plot of percentage of time that INR was in therapeutic range over 6 
months of warfarin therapy  
  
Solid bars represents means and standard deviation. The dotted line is at the                       
TTR target (INR in therapeutic range for 65% of the time). TTR below the target indicates 
inadequate INR control.  
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Fig. 2. Scatter plot of the percentage of time the INR was in the therapeutic 
range over 6 months of warfarin therapy. Solid bars represent means and 
standard deviations. The dotted line is at the TTR target (INR in therapeutic 
range for 65% of the time). TTR below the target indicates inadequate INR 
control. (INR = international normalised ratio; TTR = time in therapeutic 
range; MPC = Mitchell’s Plain Community Health Centre; GSH = Groote 
Schuur Hospital.)
Table 2. Multivariate logistic regression model of associations with good anticoagulation control (TTR ≥65%) over 6 months  
(363 patients included in the model)
 Univariate analysis Multivariate analysis
Variable Category TTR ≥65%, n (%) OR (95% CI) Wald test p-value Adjusted OR (95% CI) Wald test p-value
Age <55 years 34/177 (19.2) ref - ref -
 ≥55 years 57/186 (30.6) 1.86 (1.14 - 3.02) 0.013 1.69 (1.03 - 2.79) 0.039
Sex Female 56/238 (23.5) ref - ref -
Male 35/125 (28.0) 1.26 (0.77 - 2.07) 0.351 1.21 (0.73 - 1.99) 0.451
Site MPC 44/151 (29.1) ref -  ref -
 GSH 47/212 (22.2) 0.69 (0.43 - 1.12) 0.132  0.85 (0.50 - 1.46) 0.560
INR target 2 - 3* 57/197 (28.9) ref - ref -
2.5 - 3.5† 34/166 (20.5) 0.63 (0.39 - 1.03) 0.065 0.75 (0.43 - 1.30) 0.312
TTR = time in therapeutic range; INR = international normalised ratio; OR = odds ratio; CI = confidence interval; MPC = Mitchell’s Plain Community Health Centre;  
GSH = Groote Schuur Hospital.
*INR target 2 - 3: atrial fibrillation, pulmonary embolus, venous thromboembolism, systemic lupus erythematosus, hypercoagulable states, atrial flutter.
†INR target 2.5 - 3.5: valvular heart disease.
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hospital stay of 6 days (IQR 4 - 8.5) for all bleeds related to warfarin 
and non-steroidal anti-inflammatory drugs was recorded. [11] In 
an American study, INR instability was associated with higher 
healthcare utilisation, driven by increased length of hospital stay.[21]
Direct oral anticoagulants (DOACs) are an alternative to warfarin. 
DOACs have a number of advantages, but are expensive when 
the direct cost is considered and therefore currently not routinely 
available in the SA public sector. DOACs have more rapid onset than 
warfarin, do not require heparin bridging, have fixed doses, are less 
susceptible to food and drug-drug interactions and do not require 
routine anticoagulation monitoring.[9,22-24] A meta-analysis of stroke 
prevention in AF patients comparing three DOACs (rivaroxaban, 
dabigatran and apixaban) with VKAs, published in 2017, found a 
significantly lower risk of intracranial haemorrhage with DOACs, 
with similar efficacy to that of DOACs.[25] However, warfarin therapy 
is likely to remain an important anticoagulant option in our setting, 
as DOACs are currently not easily accessed in the public healthcare 
sector. In addition, poor TTR control may be compounded by 
suboptimal warfarin dose adjustment practice. In SA, healthcare 
workers may prescribe half-tablet dosages in order to achieve a 
warfarin dose less than the only available 5 mg strength. A study 
comparing warfarin measured half-tablet drug content against target 
drug content found that a third of half-tablets fell outside of the 
proxy United States Pharmacopeia specification.[26] These findings 
suggest that warfarin may not always be uniformly distributed within 
the tablets, which may contribute to the variability and difficulty 
in achieving effective warfarin dose titration. Individualised small 
incremental dose adjustments may therefore not always be possible.
Study limitations
Our study has several limitations. We did not have data on some 
covariates such as concomitant comorbid disease, including hepatic 
or cardiac dysfunction, interacting medications and diet, which could 
affect anticoagulation control. Data on warfarin adherence, dosing 
recommendations or adherence to dose adjustment recommendations 
were not available. Patients with >70-day gaps between INRs were 
excluded, in line with recommendations for the Rosendaal method. [13] 
This may bias towards inclusion of more adherent patients, as patients 
missing clinic visits would be excluded. Despite this potential for bias, 
TTR was low in our included patients. Patients with <27  months 
of follow-up were not included, and this exclusion may also have 
introduced some bias, as patients with an indication for long-term 
anticoagulation who died before 27 months were not eligible for 
inclusion. For patients with ‘unknown indication’ we assumed a lower 
INR target level. This may have biased TTR control positively if the 
higher target (INR 2.5 - 3.5) was required. Although our total sample 
from the two sites exceeded the 346 patients required based on our 
power calculation, we were only able to include 152 patients who 
were eligible for inclusion from the MPC site. We therefore did not 
meet the power requirement to detect a 15% TTR difference between 
the two sites. The Rosendaal method to calculate TTR, which is the 
widely recommended method for describing anticoagulation control, 
also has certain limitations, particularly when individual INR values 
are far outside the recommended therapeutic range, as it assumes that 
the change in INR over time is linear between each time-point, which 
may not always be true. Our TTR target of ≥65% is derived from 
studies in AF, and may be too conservative for patients with VHD.
Despite these limitations, this study provides good evidence in 
clinical practice of inadequate anticoagulation control in patients 
attending two high-volume INR clinics located in an urban SA 
community healthcare centre and at a tertiary academic hospital.
Conclusions
We found poor levels of anticoagulation control in our longitudinal 
study at two large urban dedicated SA INR clinics. Poor INR control 
places patients at risk of complications due to toxicity or lack of 
efficacy of therapy. Further research identifying predictors of poor 
control is required. The impact of poor anticoagulation control 
on clinical outcomes and healthcare costs in SA patients requires 
quantification. Warfarin therapy is likely to remain an important 
anticoagulant option in our setting, until the affordability and hence 
accessibility of alternative agents in SA conditions have been formally 
assessed. Evidence-based, locally validated algorithms to guide 
warfarin dose adjustment are urgently needed. The only warfarin 
formulation currently available in the public sector is the 5 mg tablet. 
Lower warfarin dosage formulations may optimise individual dose 
titration, and advocacy for these formulations is advised.
Acknowledgements. The authors gratefully acknowledge the study 
patients and the nursing staff at the two prothrombin clinics, MPC and 
GSH. Special acknowledgement goes to Dr J P Mouton and Mr William 
Msemburi for their support in statistics and extraction of the data. We 
also thank Annemie Stewart for creating the data base, Nicky Kramer for 
her contribution during the protocol development and Dawn Rossiter 
for editing. Lastly, we thank the National Health Laboratory Service for 
providing patient INR data.
Author contributions. Study concept and design: IE, MB and AB. Drafting 
of the manuscript: IE, MB, AB and KC. Statistical analysis and statistical 
support: IE, JPM, WM and KC. Interpretation of the data: all authors. 
Critical revision of the manuscript for important intellectual content: all 
authors.
Funding. None.
Conflicts of interest. None.
1. Singer D, Albers G, James D, et al. Antithrombotic therapy in atrial fibrillation. Chest 
2008;133(6):546S-592S. https://doi.org/10.1378/chest.08-0678
2. South African Medicine Research Council. South African Burden of Disease report 2000. www.mrc.
ac.za/bod (accessed 16 January 2016).
3. Horton R. Global disease burden GBD 2010: Understanding disease, injury, and risk. Lancet 
2012;380(9859):2053-2054. https://doi.org/10.1016/S0140-6736(12)62133-3
4. Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J 
Angiol 2012;21(4):187-194. https://doi.org/10.1055/s-0032-1330232
5. Hylek EM. Vitamin K antagonists and time in the therapeutic range: Implications, challenges, and 
strategies for improvement. J Thromb Thrombolysis 2013;35(3):333-335. https://doi.org/10.1007/s11239-
013-0900-5
6. Cannegieter S, Rosendaal F, Briet E. Thromboembolic and bleeding complications in patients with 
mechanical heart valve prostheses. Circulation 1994;89:635-641. https://doi.org/10.1161/01.CIR.89.2.635
7. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial 
fibrillation: A meta-analysis. Ann Intern Med 1999;131(7):492-501. https://doi.org/10.7326/0003-4819-
131-7-199910050-00042
8. Bryer A. New antithrombotic drugs? A revolution in stroke management (Editorial). Cardiovasc J Afr 
2012;23(2):61-62. http://www.cvja.co.za/onlinejournal/vol23/vol23_issue2/files/assets/basic-html/index.
html#7 (accessed 24 April 2018).
9. Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: Evidence from a meta-
analysis of randomized trials. J Am Geriatr Soc 2014;62(5):857-864. https://doi.org/10.1111/jgs.12799
10. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in 
atrial fibrillation depends on the quality of international normalized ratio control achieved by centers 
and countries as measured by time in therapeutic range. Circulation 2008;118:2029-2037. http://doi.
org/10.1161/CIRCULATIONAHA.107.750000
11. Mouton JP, Njuguna C, Kramer N, et al. Adverse drug reactions causing admission to medical wards. 
Medicine (Baltimore) 2016;95(19):1-10. https://doi.org/10.1097/MD.0000000000003437
12. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin 
at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: 
An analysis of the RE-LY trial. Lancet 2010;376(9745):975-983. https://doi.org/10.1016/S0140-
6736(10)61194-4
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of 
oral anticoagulant therapy. Thromb Haemost 1993;69(3):236-239.
14. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients 
with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. https://doi.
org/10.1161/CIRCOUTCOMES.108.796185
15. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for 
Medical Research Involving Human Subjects. JAMA 2013;310(20):2191-2194. https://doi.org/10.1001/
jama.2013.281053
16. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001;47(1):45-
50. http://www.jpgmonline.com/text.asp?2001/47/1/45/235 (accessed 3 August 2017).
17. Barth DD, Zühlke LJ, Joachim A, et al. Effect of distance to health facility on the maintenance of INR 
therapeutic ranges in rheumatic heart disease patients from Cape Town? No evidence for an association. 
BMC Health Serv Res 2015;15(219):1-7. https://doi.org/10.1186/s12913-015-0890-4
494       June 2018, Vol. 108, No. 6
RESEARCH
18. Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients 
on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Primary Health Care Fam 
Med 2016;8(1):1-8. https://doi.org/10.4102/phcfm.v8i1.1032
19. Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among 
inpatients on warfarin therapy? A prospective observational study. Thromb J 2014;12:20. https://doi.
org/10.1186/1477-9560-12-20
20. Wieloch M, Sjlander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control 
in Sweden: Reports of time in therapeutic range, major bleeding, and thrombo-embolic complications 
from the national quality registry AuriculA. Eur Heart J 2011;32(18):2282-2289. https://doi.
org/10.1093/eurheartj/ehr134
21. Laliberté F, Pilon D, Raut MK, et al. Is rivaroxaban associated with lower inpatient costs compared to 
warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30(8):1521-
1528. https://doi.org/10.1185/03007995.2014.916159
22. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. 
Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation? 
A  systematic review and meta-analysis of subgroups. Thrombosis 2013  (2013), Article ID  640723. 
https://doi.org/10.1155/2013/640723
23. Ymer M, Agon M, Shkelzen D, et al. New oral anticoagulants? Their advantages and disadvantages 
compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic 
events. Ther Clin Risk Manag 2015;11:967-977. https://doi.org/10.2147/TCRM.S84210
24. Verheugt FA. The new oral anticoagulants. Neth Heart J 2010;18(6):314-318. https://doi.org/10.1182/
blood-2009-09-241851
25. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip G. Real-world setting comparison 
of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention 
in atrial fibrillation: A systematic review and meta-analysis. Stroke 2017;48(9):2494-2503. https://doi.
org/10.1161/STROKEAHA.117.017549
26. Hill S, Varker AS, Karlage K, Myrdal PB. Analysis of drug content and weight uniformity for half-
tablets of 6 commonly split medications. J Manag Care Spec Pharm 2009;15(3):253-261. https://doi.
org/10.18553/jmcp.2009.153.253
Accepted 2 February 2018.
